Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B10 L-BPA-Based BNCT in Unresectable Recurrent Head and Neck Cancers
NCT06952868Phase 2Recruiting
- Sponsor
- China Medical University Hospital
- Start
- May 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of borofalan (10B) in head and neck cancer (HNC), sponsored by China Medical University Hospital. Primary endpoint: Assessment of the Efficacy of B10 L-BPA-Based BNCT at 6 months. Started May 2025; status: recruiting.
02
Drugs
borofalan (10B)
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT06952868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06952868.